Search clinical trials for: camrelizumab；Rivoceranib

Total 438 results

Hebei Medical University Fourth Hospital

Not yet recruiting

To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer

Pancreatic Cancer

China
Zhejiang Cancer Hospital
Zhejiang Provincial People's Hospital; Jinhua Municipal Central Hospital; Huizhou... and other collaborators

Not yet recruiting

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Esophageal Cancer

China
Eye & ENT Hospital of Fudan University
Chinese Academy of Medical Sciences

Recruiting

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
XIANG YANQUN

Not yet recruiting

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Nasopharyngeal Carcinoma
Yue Han
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Unresectable Hepatocellular Carcinoma

China
Fudan University

Recruiting

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Malignant Melanoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Breast Cancer

China
Third Affiliated Hospital, Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Locally Advanced Gastric Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial (MAGIC)

Multiple Primary Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Cervical Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Head and Neck Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer (IMCORT-2)

Non-small Cell Lung Cancer Metastatic

China
Chinese PLA General Hospital

Not yet recruiting

Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer

Gastric Cancer

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

Cervical Cancer
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Rectal Cancer

China
Shanghai Zhongshan Hospital

Enrolling by invitation

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

Hepatocellular Carcinoma

China
Beijing Chao Yang Hospital

Recruiting

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer (NACSOC-02)

Colorectal Cancer | Obstruction | Immunotherapy | Neoadjuvant Chemotherapy | Stent

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Fudan University

Unknown

PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer

Metastatic Gastric Cancer | Locally Advanced Gastric Adenocarcinoma

China
Peking University

Not yet recruiting

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Thoracic Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET-III)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
Elevar Therapeutics

Completed

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Cancer

United States
Peking University Cancer Hospital & Institute
Beijing Nanjiao Cancer Hospital

Recruiting

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

Rectal Cancer

China
West China Hospital

Not yet recruiting

A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

Head and Neck Neoplasms
Fudan University

Recruiting

Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients

Squamous Cell Carcinoma of Head and Neck

China
Tongji Hospital

Recruiting

A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC (CCGLC-005)

Intrahepatic Cholangiocarcinoma

China
Fudan University

Not yet recruiting

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer

Oligometastatic Gastrointestinal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC (Compass-001)

Non-Small Cell Lung Cancer

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Cancer | Chemotherapy | Radiotherapy | PD-1 Therapy

China
Zhenzhen Liu

Recruiting

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer | Camrelizumab

China
Tongji University
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Camrelizumab
Sun Yat-sen University

Recruiting

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
Elevar Therapeutics

Terminated

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Fujian Medical University

Not yet recruiting

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

Locally Advanced Gastric Cancer

China
Shanghai Proton and Heavy Ion Center

Recruiting

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer

Unresectable Gallbladder Cancer

China
Fudan University

Not yet recruiting

Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy

Metastatic Liver Cancer

China
Jiangsu Cancer Institute & Hospital

Recruiting

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Asan Medical Center

Recruiting

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

Korea, Republic of
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

China
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Advanced Cervical Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Henan University...

Recruiting

Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer

Esophageal Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China

3

Subscribe